Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Efficacy of Orally Administered VTS-K for Pain Management

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years+~* presenting to Maimonides Medical Center ED~* acute musculoskeletal painful conditions (traumatic and non-traumatic) with an initial pain score of 5 on a standard 11- point (0 to 10) numeric rating scale~* be awake, alert, and oriented to person, place, and time,~* demonstrate understanding of the informed consent process and content.~* have to demonstrate ability to verbalize the nature of any adverse effects they might experience as well as to express their pain severity by using the NRS.~Exclusion Criteria:~* Patients with altered mental status~* allergy to aspirin and ketamine~* pregnant patients~* unstable vital signs (systolic blood pressure \<90 or\>180 mm Hg~* pulse rate \<50 or \>150 beats/min~* respiration rate \<10 or \>30 breaths/min)~* inability to provide consent~* consumption of Aspirin or NSAID's within 6 hours of arrival to the ED~* active PUD~* history of GI Hemorrhage~* history of renal and hepatic insufficiency~* past medical history of alcohol or drug abuse~* schizophrenia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Vitalis Pharmaceuticals (VTS)-Aspirin and Ketamine (Type: None): An oral combination drug of VTS-Aspirin and ketamine (VTS-K) would facilitate the shift from IV opioids to a non-IV therapy for patients presenting to the ED with acute MSK pain. This formulation has a potential to provide effective analgesia in the ED with reduced side effects. VTS-K's proprietary oral formulation of established, safe, and well-understood APIs, makes it uniquely appropriate for use in the ED. VTS-K is administered orally, which is suitable for resource-poor environments in which the healthcare setting may be inadequate as well as suitable to improve the throughput of ED Patients by reducing their length of stay. This is especially pertinent given the alternative of IV opioids for pain management of acute MSK pain, which requires both clinical monitoring and equipment, whereas VTS-K promotes weaning off opioids, alleviating the resource consumption.

Based on this trial design, predict the completion outcome and termination type (if applicable).